Navigation Links
Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
Date:6/12/2008

WALTHAM, Mass., June 12 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) today reported results for the fourth quarter and fiscal year 2008, ended March 31, 2008. Total revenue for fiscal year 2008 was $19,296,000 compared to total revenue of $14,074,000 for fiscal year 2007 ended March 31, 2007, an increase of $5,222,000 or 37%. Total revenue for the year consisted primarily of Protein A and SecreFlo(R) product revenue.

Operating expenses for fiscal year 2008, excluding the $40,170,000 net gain from litigation previously reported in our second quarter as a result of our settlement with ImClone Systems, Inc., were $23,574,000 compared to $15,900,000 in fiscal year 2007. The increase in operating expenses of $7,674,000 was primarily the result of legal expenses incurred in conjunction with both the ImClone Systems, Inc. and Bristol-Myers Squibb litigations, direct material expenses associated with the increase in revenue, and increased research and development spending.

Net income for the year was $37,107,000 or $1.18 per diluted share, compared to a net loss for fiscal 2007 of $889,000 or $0.03 per diluted share. Net income includes a net gain of $40,170,000 from the litigation settlement with ImClone during the second quarter of fiscal year 2008. Cash and marketable securities as of March 31, 2008 were $60,589,000 compared to $22,627,000 as of March 31, 2007.

"During the past year, we have successfully advanced our product pipeline, achieved strong revenue growth and settled our outstanding litigations with ImClone Systems, Inc. and Bristol-Myers Squibb, resulting in substantial new resources for the company," stated Walter C. Herlihy, President and Chief Executive Officer of Repligen Corporation. "Our f
'/>"/>

SOURCE Repligen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
2. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
3. Cyberonics Reports Strong Revenue Growth and Profitability in Fiscal 2008 Fourth Quarter
4. Alfacell Reports Financial Results for Third Quarter of Fiscal 2008
5. YM BIOSCIENCES REPORTS NIMOTUZUMAB NSCLC CLINICAL DATA AT ASCO ANNUAL MEETING
6. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
7. Cord Blood America Reports CorCell, Its Major Acquisition in 2006, Turns Profitable
8. Bioheart, Inc. Reports Receipt of Notification from NASDAQ Regarding Non-Compliance with Continued Listing Requirements
9. Rosetta Genomics Reports First Quarter 2008 Financial Results
10. Genetic Engineering and Biotechnology News (GEN) Reports on Mass Spec in Drug Discovery
11. Advance Nanotech Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... PRC Clinical, the Clinical Trial ... Regenerative Medicine (ARM). The ARM counts more than ... commercialization of transformational treatments and cures for patients ... CRO focused in Clinical Trial Management, has developed ... research working with sponsors in the United States ...
(Date:5/25/2015)... The 2015 Market Research Report on ... and in-depth study on the current state of ... a focus on the Chinese situation. Major companies ... Linde Industrial Gas, Basf, Air Products, Air Liquide, ... Longsheng Group, Juhua Group, Wandali Gas, Unid(Jiangsu) Chemical, ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 Charm ... U.S. Department of Agriculture (USDA), Grain Inspection, Packers ... year contract to Charm Sciences to monitor aflatoxin ... Test (water-based) and ROSA FAST Aflatoxin Quantitative Test ... Quantitative Test uses Water Extraction Technology to ...
(Date:5/21/2015)... (PRWEB) May 21, 2015 Seventh Wave ... safety and efficacy of pharmaceutical products and medical devices, ... Heights, MO 63043, a 50,000 sq. ft. building more ... to enable strategic growth. Facility renovations will begin immediately ... new space will occur in September. , “We ...
Breaking Biology Technology:PRC Clinical Joins 200+ Member Organizations in The Alliance for Regenerative Medicine (ARM) 2PRC Clinical Joins 200+ Member Organizations in The Alliance for Regenerative Medicine (ARM) 3Global Hydrogen Chloride Industry 2015 Trends and Analysis Available in a New Report at DeepResearchReports.com 2Global Hydrogen Chloride Industry 2015 Trends and Analysis Available in a New Report at DeepResearchReports.com 3USDA-GIPSA (FGIS) Awards 5 Year Contract for Aflatoxin Tests to Charm Sciences 2Seventh Wave Laboratories Purchases Building for Expansion, Upcoming Move 2Seventh Wave Laboratories Purchases Building for Expansion, Upcoming Move 3
... team of U.S., Israeli and German scientists used computational ... role in human cell division and to identify more ... pattern of activation in cancer cells., Malignant cells have ... in cell cycle gene activation in normal and malignant ...
... ... Patients, CAMBRIDGE, ... ) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ),announced today that ... and commercialize mipomersen, Isis, lipid-lowering,treatment for high risk cardiovascular patients that ...
... Wins for Industry Leadership, JOPLIN, Mo., Jan. ... announced its Medical Power group has received,Battery Power ... received honors in the Industry Leadership category for ... battery., The Innova Award recognizes companies that ...
Cached Biology Technology:International team identifies 480 genes that control human cell division 2International team identifies 480 genes that control human cell division 3Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen 2Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen 3Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen 4Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen 5Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen 6Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen 7EaglePicher Technologies Receives Battery Power Products and Technology's First Annual Innova Award 2
(Date:5/5/2015)... , May 5, 2015, NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, reminds investors ... Chief Technology Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA ... 5-7, 2015. The three-day conference is organized ... is speaking in is themed Global Fraud: Where is ...
(Date:4/27/2015)... , Apr. 27, 2015 Profile Solutions, Inc. ... and security systems is pleased to announce that Dr ... a consultant and member of its scientific advisory board. ... known as a thought leader in technology-enhanced learning models. ... Group, and has published studies and books focused on ...
(Date:4/20/2015)... The announcement comes as demand ... Management (GRM), Ireland,s foremost records management ... built up an impressive track record of clients within the ... the records management sector in Dubai . ... staffbase and employ a further eight staff members at its ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3
... 10, 2011The mega-mergers of 2009 did not continue into 2010. ... price tag of more than $40 billion, only last year,s ... of reported deals conducted by Genetic Engineering & Biotechnology News ... the year, sanofi-aventis, move to buy Genzyme, is still being ...
... reports that several herbicides used on corn also have ... Miscanthus), a potential bioenergy feedstock. "No herbicides are ... biomass," said Eric Anderson, an instructor of bioenergy for ... of Illinois. "Our research shows that several herbicides used ...
... 20,000 to 30,000 genes (the number is hotly contested), but ... proteins. It,s the protein molecules that domost of the work ... from the Greek prota, meaning "of primary importance." Proteins ... of usually fold spontaneously into what is called their "native ...
Cached Biology News:GEN reports on biotech acquisition deals in 2010 that topped $1 billion 2Miscanthus has a fighting chance against weeds 2New method takes snapshots of proteins as they fold 2New method takes snapshots of proteins as they fold 3New method takes snapshots of proteins as they fold 4New method takes snapshots of proteins as they fold 5
...
... T7 Phage Capture Plate is a 96-well ELISA-compatible ... the T7 Tail Fiber Monoclonal Antibody is immobilized ... The antibody specifically recognizes the tail fiber protein ... has a capacity of 10 9 phage ...
... TRAPeze RT Telomerase Detection Kit ... vitro assay for the fluorometric ... of telomerase activity. It incorporates ... assay and adds the ability ...
... The expertise that made the original Gene Pulser ... system available has been applied in the Gene ... The modular design of the Gene Pulser II ... accessory that has the widest range of settings ...
Biology Products: